Contribute Try STAT+ Today

WASHINGTON — The drug industry is going all-in on its push to shift the conversation about drug prices to one about value, and its top lobbyist said the industry would be opportunistic in the coming months in finding legislative and administrative avenues to advance policies in pursuit of that goal.

The industry, represented here by the Pharmaceutical Research and Manufacturers of America, has some specific changes in mind that it says would free them to enter into more value-based contracts with health insurers. The group’s argument: Biopharmaceutical companies develop breakthrough medications that save lives, and they can be the answer to the problem of health care costs, rather than the cause.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • I am in biotech drug discovery professional and the concept of value-based pricing sounds good, and we it is a necessary new guideline, and there are healthcare cost containment reasons for it, but it seems that from the drug pricing or overall costs of therapy points of views there will still need to be floors and cap on drug pricing. For a life-saving drug, does this mean a price of $1M/year? The EMA does this type of rational price control. And conversely the prices can not be too low or manufacturers will not keep producing and selling the drug. And what happens for symptomatic treatment drugs for very large populations such as Alzheimer’s? So a good article would be on, what are we talking about when we use this term? Thanks.

Comments are closed.